Trial Profile

A Phase Ib Study to Evaluate Efficacy, Safety and Tolerability of KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anbenitamab (Primary) ; Erfonrilimab (Primary)
Indications Gastrointestinal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

06 Apr 2024 Status changed from active, no longer recruiting to completed.
06 Mar 2023 Status changed from recruiting to active, no longer recruiting.
06 Apr 2022 Planned End Date changed from 30 Dec 2020 to 30 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com